Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10052570 | 0.94 | ERBB2 (0.32) | ERBB2 | |
| SCHEMBL12470798 | 0.78 | PDE10A (0.35) | PDE10A | |
| SCHEMBL10835168 | 0.75 | PDE10A (0.43) | PDE10A | |
| SCHEMBL10144470 | 0.75 | PDE10A (0.43) | PDE10A | |
| SCHEMBL3457245 | 0.73 | MAPK1 (0.32) | PDE10A | |
| SCHEMBL8521432 | 0.71 | PDE10A (0.30) | PDE10A | |
| SCHEMBL26492489 | 0.71 | KDM4E (0.32) | PDE10A | |
| SCHEMBL28208820 | 0.71 | PDE10A (0.30) | PDE10A | |
| SCHEMBL8518640 | 0.71 | PDE10A (0.30) | PDE10A | |
| SCHEMBL12472394 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925039-A | N- (3, 5, 6-trimethyl pyrazine-2-methylene) -huperzine A and synthetic method and application thereof | 陕西中药研究所(陕西医药信息中心) | 2023-10-24 | — | — | CN | claimed |
| CN-110483419-B | Ligustrazine/azonium dialkoxide derivative, preparation method and application thereof | 泰州学院 | 2022-11-29 | — | — | CN | claimed |
| CN-110269858-B | Twin medicine for treating ischemic stroke and preparation method thereof | 贵州医科大学 | 2021-07-09 | — | — | CN | claimed |
| CN-108350023-B | Compound with anticancer effect and preparation method and application thereof | 四川思路迪药业有限公司 | 2021-01-08 | — | — | CN | claimed |
| CN-107325058-B | Diaryl methylene disulfide compound and preparation method and application thereof | 苏州大学 | 2020-07-24 | — | — | CN | claimed |
| CN-110269858-A | It is a kind of to treat twin medicine of cerebral arterial thrombosis and preparation method thereof | 贵州医科大学 | 2019-09-24 | — | — | CN | claimed |
| CN-108350023-A | Compound with anticancer effect and preparation method and application thereof | 四川思路迪药业有限公司 | 2018-07-31 | — | — | CN | claimed |
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | claimed |
| EP-2213666-B1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | LI JIAMING (CN) | 2012-02-15 | — | — | EP | claimed |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2010-09-09 | — | — | US | claimed |
| EP-2213666-A1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | Li, Jiaming (CN) | 2010-08-04 | — | — | EP | claimed |
| CN-116925039-B | N- (3, 5, 6-trimethyl pyrazine-2-methylene) -huperzine A and synthetic method and application thereof | 陕西中药研究所(陕西医药信息中心) | 2026-04-14 | — | — | CN | disclosed |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-02 | — | — | US | disclosed |
| CN-115838356-B | Compound for treating cardiovascular and cerebrovascular diseases and preparation method thereof | 台州永健医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-117069686-B | Genipin derivative, preparation method and application thereof | 安徽中医药大学 | 2025-03-11 | — | — | CN | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | JANSSEN SCIENCES IRELAND UC (IE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | JANSSEN SCIENCES IRELAND UC (IE) | 2007-02-22 | — | — | US | disclosed |
| WO-2005058871-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058869-A1 | AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 | ERBB2 1641/4885PDE10A 4668/4885 |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3 | ERBB2 1792/4885PDE10A 4460/4885 |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | ERBB2 841/4885PDE10A 3334/4885 |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | AHR, CYP3A5, CYP3A43 | ERBB2 427/4885PDE10A 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.